TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18637755
Drug: Single-day famciclovir
Normalized name: Famciclovir
DrugBank: Famciclovir (DB00426)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-day famciclovir (1000 mg administered twice daily)
Study: 18637755
Drug: 3-day valacyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day valacyclovir (500 mg administered twice daily)
Study: 12953944
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of benzoyl peroxide 6% cleanser and tretinoin 0.1% microsphere gel
Study: 12953944
Drug: Tretinoin 0.1%
Normalized name: TRETINOIN 0.1% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin 0.1% microsphere gel (monotherapy)
Study: 3971296
Drug: Pump therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pump therapy
Study: 24699551
Drug: Intracoronary Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary Adenosine (100 µg/stented vessel)
Study: 20353387
Drug: New regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: New regimen with two or more active agents
Study: 15837451
Drug: anti-cyclooxygenase-2 non-steroidal
Normalized name: NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-cyclooxygenase-2 non-steroidal anti-inflammatory drugs (anti-COX-2 NSAIDs)
Study: 15837451
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of daily tablets of study medication
Study: 4947832
Drug: Placebo (influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (influenza vaccine)
Study: 2497130
Drug: Progesterone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (10 mg, im)
Study: 2497130
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (10 or 100 mg, orally)
Study: 19188
Drug: Clorazepate dipotassium
Normalized name: Clorazepate Dipotassium
DrugBank: Clorazepic acid (DB00628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorazepate dipotassium (15 mg) with antacid suspension
Study: 19188
Drug: Clorazepate dipotassium
Normalized name: Clorazepate Dipotassium
DrugBank: Clorazepic acid (DB00628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorazepate dipotassium (15 mg) alone
Study: 7246998
Drug: Halothane (inhalational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halothane (inhalational agent)
Study: 7246998
Drug: Enflurane (inhalational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enflurane (inhalational agent)
Study: 31800053
Drug: Higher nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher nicotine option (cigarettes ≥ 5.3 mg/g)
Study: 31800053
Drug: Nicotine nasal
Normalized name: nicotine Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine nasal spray (2.5 µg/kg)
Study: 31800053
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low or no nicotine option (cigarettes ≤ 2.3 mg/g and placebo spray)
Study: 26874820
Drug: Fractional carbon-dioxide
Normalized name: Carbon Dioxide
DrugBank: Carbon dioxide (DB09157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fractional carbon-dioxide laser-assisted topical therapy with terbinafine cream (once-daily for 3 months)
Study: 26874820
Drug: Fractional carbon-dioxide
Normalized name: Carbon Dioxide
DrugBank: Carbon dioxide (DB09157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fractional carbon-dioxide laser-assisted topical therapy
Study: 17991660
Drug: White wine
Normalized name: White wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: White wine (20 g ethanol/d for 4 weeks)
Study: 17991660
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (20 g ethanol/d for 4 weeks)
Study: 16192580
Drug: Cisplatin 80
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 80 mg/m2 IV on day 1 alone (arm A)
Study: 16192580
Drug: Cisplatin 80
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 80 mg/m2 IV on day 1 combined with raltitrexed 3 mg/m2 (arm B)
Study: 9821415
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 800 micrograms once daily
Study: 9821415
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 400 micrograms twice daily
Study: 2680179
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% minoxidil
Study: 340306
Drug: Clomipramine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (50 mg twice daily)
Study: 27781419
Drug: Tablet form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet form of mycophenolate mofetil (500 mg)
Study: 27781419
Drug: Capsule form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule form of mycophenolate mofetil (250 mg)
Study: 29131002
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume (VT) of 6 mL/kg and moderate positive end-expiratory pressure (PEEP) of 8 cm H2O
Study: 29131002
Drug: High tidal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High tidal volume (VT) of 10 mL/kg and zero end-expiratory pressure (ZEEP)
Study: 26081329
Drug: Mexidol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexidol (500 mg/day intravenously for 14 days, then 500 mg twice a day orally for 60 days)
Study: 17361495
Drug: hydroxyzine 25
Normalized name: hydroxyzine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydroxyzine 25 mg/d
Study: 17361495
Drug: doxepin 10
Normalized name: doxepin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxepin 10 mg/d
Study: 2938615
Drug: Topical azelaic
Normalized name: azelaic acid Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical azelaic acid
Study: 31144674
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily
Study: 18647810
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg daily im P administration
Study: 18647810
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg daily im P administration
Study: 16244481
Drug: Olanzapine (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (average dose 4.71 mg)
Study: 16244481
Drug: Haloperidol (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (average dose 1.75 mg)
Study: 1326348
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg isoniazid
Study: 8557903
Drug: Open control
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open control (no lisinopril)
Study: 1801054
Drug: norfloxacin 200
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: norfloxacin 200 mg at night
Study: 1801054
Drug: macrocrystalline nitrofurantoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: macrocrystalline nitrofurantoin 100 mg at night
Study: 31609296
Drug: High salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: High salt intake (3900 mg·d)
Study: 27083930
Drug: Sacubitril/valsartan (LCZ696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan (LCZ696) 400 mg
Study: 27083930
Drug: Sacubitril/valsartan (LCZ696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan (LCZ696) 1200 mg
Study: 25122979
Drug: Oscillating-rotating toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oscillating-rotating toothbrush (Oral-B Triumph with SmartGuide and FlossAction brush head)
Study: 21916999
Drug: TCH (1.35%
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCH (1.35% taurolidine, 4% citrate and 500 U/ml heparin)
Study: 18308996
Drug: Heparin 5000
Normalized name: HEPARIN 5000 UNT/ML SYRINGE 1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 5000 U/ml
Study: 17345042
Drug: Memantine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (10 mg, bi.d.)
Study: 17345042
Drug: Memantine (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (once-daily dosing)
Study: 17345042
Drug: Memantine (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (once-daily dosing during titration and short-term maintenance therapy)
Study: 12032018
Drug: Saline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (3 mL)
Study: 12032018
Drug: Lidocaine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (30 mg)
Study: 9477390
Drug: Low carotenoid
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low carotenoid diet with 0.5 mg/day of Beta-carotene (Group C)
Study: 9477390
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received 0.5 mg/day of Beta-carotene (Group C and Group P) during period 2
Study: 29707867
Drug: Fractional CO2
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO2 laser therapy followed by narrow band ultraviolet‐B (NB‐UVB) phototherapy
Study: 30275526
Drug: Azacitidine 75
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine 75 mg/m2/day x7 days
Study: 26502869
Drug: Oral UDCA
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral UDCA 4×250 mg daily (Group 1)
Study: 26502869
Drug: Intravenous SAMe
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous SAMe 1000 mg daily (Group 2)
Study: 26502869
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of UDCA and SAMe (Group 3)
Study: 24060628
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy focused on eating disorder features
Study: 24060628
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy focused on mood intolerance, clinical perfectionism, core low self-esteem or interpersonal difficulties
Study: 21883279
Drug: Five-grass-pollen daily
Normalized name: grass pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five-grass-pollen daily tablet sublingually for 4 months
Study: 8828025
Drug: Ebastine 10
Normalized name: ebastine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 10 mg/day for 2 weeks
Study: 8828025
Drug: Ebastine 10
Normalized name: ebastine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 10 mg/day for 4 months
Study: 8828025
Drug: Astemizole 10
Normalized name: astemizole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole 10 mg/day for 4 months
Study: 6741445
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml Gelusil orally (Group I, n = 17)
Study: 6741445
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of 0.3 mol/l sodium citrate (Group II, n = 16)
Study: 18024309
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 and folic acid treatment in addition to aspirin and IVIG
Study: 18024309
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and IVIG alone
Study: 15655011
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) 1500 mg and Methylene Blue (MB) 780 mg over 3 days
Study: 10448728
Drug: No implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No implant
Study: 10448728
Drug: Lyophilized dura
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized dura implant
Study: 10448728
Drug: Ethisorb implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethisorb implant
Study: 10448728
Drug: e-PTFE implant
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: e-PTFE implant
Study: 10448728
Drug: Implants (combined)
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants (combined)
Study: 10448728
Drug: Overall (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall (no implant vs implants)
Study: 8574160
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) during consolidation chemotherapy
Study: 8574160
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during consolidation chemotherapy
Study: 8574160
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) during induction chemotherapy
Study: 8574160
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during induction chemotherapy
Study: 264991
Drug: Intensified initial
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intensified initial therapy (11/73)
Study: 31364911
Drug: Wixela Inhub
Normalized name: Wixela Inhub
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Wixela Inhub (100/50 μg FP/S)
Study: 31364911
Drug: Wixela Inhub
Normalized name: Wixela Inhub
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Wixela Inhub (250/50 μg FP/S)
Study: 31364911
Drug: Wixela Inhub
Normalized name: Wixela Inhub
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Wixela Inhub (500/50 μg FP/S)
Study: 24888575
Drug: ADIM (free-mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADIM (free-mixed aspart and detemir insulin)
Study: 24888575
Drug: ANIM (premixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANIM (premixed fixed-ratio aspart and NPH insulin)
Study: 23624756
Drug: ZT-1 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZT-1 (0.5 mg, po)
Study: 23624756
Drug: ZT-1 (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZT-1 (0.75 mg, po)
Study: 23624756
Drug: ZT-1 (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZT-1 (0.75 mg/d, po) for 8 consecutive days
Study: 23624756
Drug: ZT-1 (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZT-1 (0.5, 0.75, 1, 1.25 or 1.5 mg, po)
Study: 21306949
Drug: Positional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positional therapy with therapeutic pillow
Study: 19207633
Drug: TAU (treatment‐as‐usual)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU (treatment‐as‐usual)
Study: 14760324
Drug: abciximab infusion
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: abciximab infusion for 24 hours
Study: 14760324
Drug: abciximab infusion
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: abciximab infusion for 48 hours
Study: 12213991
Drug: GP IIb/IIIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP IIb/IIIa treatment group
Study: 9644739
Drug: Anticytokine antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticytokine antibodies (including TNF antibodies)
Study: 9644739
Drug: TNF antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF antibodies (both in monotherapy and in combination with other anticytokines)
Study: 9644739
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to interferon gamma
Study: 9644739
Drug: Antibodies to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies to interferon-alpha
Study: 3346412
Drug: 10 mumol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mumol/L 15-HETE
Study: 3346412
Drug: 1 mumol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mumol/L 15-HETE
Study: 3346412
Drug: 0.1 ml
Normalized name: ethanol 0.1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 ml of 10 mumol/L 15-HEPE
Study: 26108960
Drug: Levodopa medication
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa medication
Study: 18192882
Drug: FLEC regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLEC regimen (5-fluorouracil 1000 mg/m2, leucovorin 100 mg/m2, epirubicin 60 mg/m2, carboplatin 300 mg/m2 administered every 3 weeks)
Study: 1952874
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of cefprozil once a day for 10 days (n = 72)
Study: 1952874
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of cefaclor three times a day for 10 days (n = 36)
Study: 7291694
Drug: Almitrine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine (0.5 mg/kg IV followed by 2 mg/kg infusion for 2 hours)
Study: 31254051
Drug: Intravitreal injections
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injections of anti-VEGF
Study: 28346813
Drug: Pooled protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled protein treatments (PB + WP = PRO)
Study: 19388923
Drug: Jet-delivered lidocaine
Normalized name: lidocaine Jet Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet-delivered lidocaine (0.2 mL of buffered 1% lidocaine)
Study: 19388923
Drug: Jet-delivered placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet-delivered placebo (0.2 mL of preservative-free normal saline)
Study: 16686553
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (4 x d(‐1) x 5 g creatine monohydrate + 1 g maltodextrin)
Study: 16686553
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 x d(‐1) x 6 g maltodextrin)
Study: 11514041
Drug: Budesonide, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide, 200 microg (for patients < 11 years) or 400 microg (for patients >= 11 years), administered once daily via Turbuhaler for 3 years
Study: 11514041
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered once daily via Turbuhaler for 3 years
Study: 8354768
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amitriptyline and perphenazine
Study: 20206791
Drug: Intact tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact tablets under fasting conditions
Study: 20206791
Drug: Intact tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact tablets under fed conditions
Study: 20206791
Drug: Dissolved tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dissolved tablets under fasting conditions
Study: 16889053
Drug: Amlodipin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipin monotherapy (mean dose 8.9 ± 0.6 mg/day)
Study: 16889053
Drug: Lisinopril monotherapy
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril monotherapy (mean dose 17.5 ± 1.4 mg/day)
Study: 16889053
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with amlodipin (6.8 ± 0.7 mg/day) and lisinopril (8.7 ± 0.6 mg/day)
Study: 14578370
Drug: Oxandrolone 20
Normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxandrolone 20 mg/day for 12 weeks
Study: 11370551
Drug: Preoperative radiochemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiochemotherapy (50.4 Gy total dose, 1.8 Gy single dose, 5-FU 1,000 mg/m2/d for 120 hours in weeks 1 and 5, 4 cycles of 5-FU 500 mg/m2/d i.v. bolus)
Study: 11370551
Drug: Postoperative radiochemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiochemotherapy (50.4 Gy total dose, 1.8 Gy single dose, 5-FU 1,000 mg/m2/d for 120 hours in weeks 1 and 5, 4 cycles of 5-FU 500 mg/m2/d i.v. bolus)
Study: 8215669
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of ceftriaxone
Study: 3302845
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of ceftriaxone
Study: 26997378
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 supplementation (100 μg/mL intravenously, two times a week for eight weeks)
Study: 22737716
Drug: 0.3 mg/5
Normalized name: Calcium Pantothenate/Cyanocobalamin/Iron/Magnesium/Manganese/Niacin/Pyridoxine/Riboflavin/Thiamine/Zinc 1.67 MG/5 ML-0.00017 MG/5 ML-2.5 MG/5 ML-8.3 MG/5 ML-0.17 MG/5 ML-0.42 MG/5 ML-0.83 MG/5 ML-0.3 MG/5 ML Oral Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/5 ml scopolamine
Study: 22737716
Drug: 4 mg/5
Normalized name: Pediox, 4 mg/5 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/5 ml ondansetron
Study: 22737716
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg scopolamine plus 4 mg ondansetron per 5 ml
Study: 22737716
Drug: 0.9% normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline 5 ml (control group)
Study: 19643947
Drug: SCH527123 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH527123 (50 mg once daily, 4 days)
Study: 19643947
Drug: Prednisolone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (50 mg once)
Study: 15207942
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CBT and light therapy
Study: 15207942
Drug: Light therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light therapy alone
Study: 11511559
Drug: Lansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 60 mg followed by 30 mg four times daily
Study: 11511559
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 2 g followed by 1 g four times daily